Kailera Therapeutics reported a net loss of $111.3 million for the quarter ended June 30, 2026, compared to $28.9 million in the prior year period. Research and development expenses increased to $101.1 million from $19.5 million due to higher clinical and manufacturing costs, while general and administrative expenses rose to $20.3 million from $11.1 million. The company held $1,171.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing a runway into mid-2028. Pipeline updates include the full enrollment of the Phase 2b high-dose ribupatide injection trial with data expected in mid-2027, an active IND for oral ribupatide with global Phase 3 initiation planned for early 2027, and ongoing Phase 2 development for KAI-7535. The company also appointed Nur Nicholson as Chief Technology Officer and Kathleen Tregoning as Chief Corporate Affairs Officer to expand its executive team. Kailera Therapeutics is a clinical-stage biotechnology company focused on developing obesity treatments using GLP-1-based mechanisms.